Skip to Content
Learn about Brilinta and how it may lower your risk of having a stroke

Aspirin / dipyridamole Pregnancy and Breastfeeding Warnings

Aspirin / dipyridamole is also known as: Aggrenox

Medically reviewed on Feb 15, 2018

Aspirin / dipyridamole Pregnancy Warnings

Animal studies have revealed a resorption rate that approached 100%, indicating potentiation of aspirin-related fetotoxicity at doses that produced maternal weight loss. In humans, use of aspirin during the later stages of pregnancy may cause low birth weight, increased incidence of intracranial hemorrhage in premature infants, stillbirths, and neonatal death. Also in humans, nonsteroidal anti-inflammatory drugs (NSAIDs) are known to cause premature closure of the fetal ductus arteriosus. There are no controlled data in human pregnancy.

Aspirin can cause excessive blood loss at delivery as well as prolonged gestation and labor.

AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended during the first two trimesters of pregnancy unless clearly needed; use should be avoided during the third trimester of pregnancy.

AU TGA pregnancy category: C
US FDA pregnancy category: D

Comments: If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Aspirin / dipyridamole Breastfeeding Warnings

US: Use should be avoided.
UK: Benefit should outweigh risk.
AU: Caution is recommended.

Excreted into human milk: Yes (aspirin, dipyridamole)

Comments: According to some experts, low-dose aspirin (75 to 162 mg daily) may be considered for antiplatelet therapy in breastfeeding women. Avoiding breastfeeding for 1 to 2 hours following a low dose of aspirin may minimize the risk of antiplatelet effects in the infant.

See references

References for pregnancy information

  1. "Product Information. Aggrenox (aspirin-dipyridamole)" Boehringer-Ingelheim, Ridgefield, CT.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  4. "Product Information. Aggrenox (aspirin-dipyridamole)" Boehringer-Ingelheim, Ridgefield, CT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.